Terns Pharmaceuticals/TERN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

Ticker

TERN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Amy Burroughs

Employees

66

Headquarters

Foster city, United States

TERN Metrics

BasicAdvanced
$389M
Market cap
-
P/E ratio
-$1.26
EPS
-
Beta
-
Dividend rate
$389M
$13.03
$3.26
973K
27.854
-33.23%
-34.73%
-34.55%
1.641
1.642
20.57%

What the Analysts think about TERN

Analyst Ratings

Majority rating from 8 analysts.
Buy

TERN Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$22M
6.19%
Profit margin
0.00%
NaN%

TERN Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 11.11%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.25
-$0.42
-$0.29
-$0.30
-
Expected
-$0.34
-$0.31
-$0.29
-$0.34
-$0.34
Surprise
-26.23%
37.45%
-0.76%
-11.11%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Terns Pharmaceuticals stock?

Terns Pharmaceuticals (TERN) has a market cap of $389M as of June 20, 2024.

What is the P/E ratio for Terns Pharmaceuticals stock?

The price to earnings (P/E) ratio for Terns Pharmaceuticals (TERN) stock is 0 as of June 20, 2024.

Does Terns Pharmaceuticals stock pay dividends?

No, Terns Pharmaceuticals (TERN) stock does not pay dividends to its shareholders as of June 20, 2024.

When is the next Terns Pharmaceuticals dividend payment date?

Terns Pharmaceuticals (TERN) stock does not pay dividends to its shareholders.

What is the beta indicator for Terns Pharmaceuticals?

Terns Pharmaceuticals (TERN) does not currently have a Beta indicator.

What is the Terns Pharmaceuticals stock price target?

The target price for Terns Pharmaceuticals (TERN) stock is $14.21, which is NaN% below the current price of $. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Terns Pharmaceuticals stock

Buy or sell Terns Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing